CTOR (Citius Oncology) FCF Margin %: -265.87% (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.66
! 2 Warning Signs
View Full Analysis

What is Citius Oncology FCF Margin %?

Citius Oncology CTOR 10 FCF Margin % is -265.87% as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 958 Drug Manufacturers companies, Citius Oncology ranks worse than 94.99% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Citius Oncology's Free Cash Flow for the three months ended in Mar. 2026 was $-4.43 Mil. Citius Oncology's Revenue for the three months ended in Mar. 2026 was $1.67 Mil. Therefore, Citius Oncology's FCF Margin % for the quarter that ended in Mar. 2026 was -265.87%.

As of today, Citius Oncology's current FCF Yield % is -26.38%.

The historical rank and industry rank for Citius Oncology's FCF Margin % or its related term are showing as below:

CTOR' s FCF Margin % Range Over the Past 10 Years
Min: -288.49   Med: 0   Max: 0
Current: -288.49

CTOR's FCF Margin % is ranked worse than
94.99% of 958 companies
in the Drug Manufacturers industry
Industry Median: 2.51 vs CTOR: -288.49

Citius Oncology FCF Margin % Related Terms

Citius Oncology FCF Margin % Historical Data

* Premium members only.

The historical data trend for Citius Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology FCF Margin % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
FCF Margin %
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -298.05 -265.87

CTOR vs INCR, BGM, CPIX: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's FCF Margin % falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Citius Oncology's FCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-11.242/0
= %

Citius Oncology's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.432/1.667
=-265.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -265.87% mean?
Citius Oncology (CTOR) has a FCF Margin % of -265.87% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #910 out of 958 companies in the Drug Manufacturers industry, placing it in the top 95%.
Is Citius Oncology's FCF Margin % too high?
Citius Oncology's current FCF Margin % is -265.87%. Based on the distribution chart, Citius Oncology ranks #910 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's FCF Margin % compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #910 out of 958 companies for FCF Margin %. This places Citius Oncology in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current FCF Margin % is -265.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current FCF Margin % of -265.87%. The current FCF Margin % is -265.87%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current FCF Margin % is -265.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price